Mountain View-based Conceptus produces Essure, a permanent birth control procedure performed by doctors in their offices by placing flexible micro-inserts in the fallopian tubes without cutting, general anesthesia or hormones. In three months the product creates a natural barrier that keeps sperm from reaching eggs.
Founded in 1992, the company won U.S. Food and Drug Administration approval in 2002 to market Essure. Conceptus (Nasdaq: CPTS) reported second-quarter revenues of $34 million and net income of $500,000, compared to a year-ago loss of $2.9 million on revenues of $37 million.
